Peripheral lipopolysaccharide administration impairs two-way active avoidance conditioning in C57BL/6J mice. Physiol Behav
Department of Psychology, Texas Christian University, TCU Box 298920, Fort Worth, TX 76129, USA. Physiology & Behavior
(Impact Factor: 2.98).
07/2005; 85(3):278-88. DOI: 10.1016/j.physbeh.2005.04.015
Peripheral administration of lipopolysaccharide (LPS) or interleukin-1 (IL-1) may lead to alterations of CNS function and behavioral changes designated "sickness behavior." Further, some experiments show evidence of LPS- and cytokine-mediated alterations in learning and memory. The current series of experiments examined the effects of a single or repeated intraperitoneal LPS injections, at a number of doses and time points before or after test sessions, on behavior in a two-way active avoidance conditioning paradigm. Subjects were able to avoid the mild shock stimulus, escape it, or fail to respond to it. Subjects treated with LPS at many, but not all, of the time points sampled showed impaired learning, by exhibiting significantly fewer avoidance responses than controls. Furthermore, an LPS-induced increase in non-cued inter-trial interval crossings was observed during the later days of testing, suggesting that a greater percentage of their avoidance responses was not conditioned and their behavior was less efficient. Taken together, the results suggest that LPS-treated animals showed a diminished association between conditioned stimulus (CS) and unconditioned stimulus (US). These results support the theory that peripheral immune stimuli may induce deleterious effects on learning, and extend the work to a negatively reinforced operant procedure.
Available from: Lindsey N Sadler
- "Lipopolysaccharide (LPS) is a bacterial endotoxin known to activate the innate immune system and trigger increases in both central and peripheral production of pro-inflammatory cytokines, including interleukin-1␤ (IL-1␤) . Moreover, inflammation as a result of peripheral LPS administration has been shown to impair acquisition, consolidation, and reconsolidation of information in learning and memory paradigms   , including contextual fear conditioning, a hippocampus-dependent task that lends itself well to discriminating between sickness behavior and actual memory decrements. Although the exact mechanisms mediating the behavioral effects of LPS administration remains unknown, the clear connection with inflammation is supported by evidence showing that administration of IL-1␤ to the dorsal hippocampus is sufficient to partially replicate LPS-induced memory impairments . "
[Show abstract] [Hide abstract]
ABSTRACT: Recent evidence suggests that inflammation-induced decrements in cognitive function can be mitigated via manipulation of excitatory or inhibitory transmission. We tested the ability of the inverse benzodiazepine agonist, MRK-016 (MRK) to protect against LPS-induced deficits in memory acquisition and consolidation, using a contextual fear conditioning (CFC) paradigm. In Experiment One, mice received lipopolysaccharide (LPS) and/or MRK injections prior to CFC training, and were then tested 24hours after training. In Experiment Two, animals received similar treatment injections immediately after training, and were tested 24hours later. Additionally, hippocampal samples were collected four hours after LPS injections and immediately after testing, to evaluate brain-derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF-1) mRNA expression. Results indicate that MRK can protect against LPS-induced learning/memory decrements in both paradigms. We also found, in both paradigms, that animals treated with LPS/Saline expressed significantly less BDNF mRNA when compared to Saline/Saline-treated animals four hours after LPS administration, but that MRK did not restore BDNF expression levels. Further, treatment administrations had no effect on IGF-1 mRNA expression at any collection time-point. In summary, MRK-016 can protect against LPS-induced deficits in memory acquisition and consolidation, in this hippocampus-dependent paradigm, though this protection occurs independently of recovery of BDNF expression.
Copyright © 2015. Published by Elsevier B.V.
Behavioural brain research 03/2015; 288. DOI:10.1016/j.bbr.2015.03.048 · 3.03 Impact Factor
Available from: Arnaud Le Rouzic
- "Jaumann et al. (2013) showed that starved bees displayed poorer learning , and long-term memory formation is known to reduce tolerance to starvation in Drosophila (Mery and Kawecki 2005). Adverse effects of infection or immune system activation on learning performance in rodents (Kavaliers et al. 1995; Gibertini et al. 1995; Sparkman et al. 2005) and bees (Mallon et al. 2003; Gegear et al. 2006) also point to similar physiological links between learning and immune defense (although see Babin et al. 2014b or an opposite result). "
[Show abstract] [Hide abstract]
ABSTRACT: Even though laboratory evolution experiments have demonstrated genetic variation for learning ability, we know little about the underlying genetic architecture and genetic relationships with other ecologically relevant traits. With a full diallel cross among twelve inbred lines of Drosophila melanogaster originating from a natural population (0.75 < F < 0.93), we investigated the genetic architecture of olfactory learning ability and compared it to that for another behavioral trait (unconditional preference for odors), as well as three traits quantifying the ability to deal with environmental challenges: egg-to-adult survival and developmental rate on a low-quality food, and resistance to a bacterial pathogen. Substantial additive genetic variation was detected for each trait, highlighting their potential to evolve. Genetic effects contributed more than nongenetic parental effects to variation in traits measured at the adult stage: learning, odorant perception, and resistance to infection. In contrast, the two traits quantifying larval tolerance to low-quality food were more strongly affected by parental effects. We found no evidence for genetic correlations between traits, suggesting that these traits could evolve at least to some degree independently of one another. Finally, inbreeding adversely affected all traits.
Ecology and Evolution 02/2015; 5(3). DOI:10.1002/ece3.1379 · 2.32 Impact Factor
Available from: Michael Chumley
- "Intraperitoneal (i.p.) injections of LPS (Escherichia coli, serotype 0111:B4; Sigma, St. Louis, MO) were given at the dose of 250 g/kg, and i.p. injections of DCS (Sigma, St. Louis, MO) were given at the dose of 15 mg/kg in sterile, pyrogen-free 0.9% saline (Baxter, Deerfield, IL). Doses for both LPS and DCS were derived from previously published literature (LPS         ). More specifically, we utilized LPS at the dose of 250 g/kg as prior work has shown that this dose reliably induces sickness behavior and learning deficits in rodents (e.g., ), and we utilized DCS at the dose of 15 mg/kg as previously published literature indicates that this dose reliably facilitates various forms and phases of learning and memory, including memory consolidation (e.g., ). "
[Show abstract] [Hide abstract]
ABSTRACT: In the current study, the partial NMDA receptor agonist D-cycloserine (DCS) rescued memory consolidation following systemic bacterial endotoxin exposure. DCS failed, however, to restore hippocampal BDNF mRNA levels that were diminished following a systemic administration of LPS, and did not alter NR1 or NR2C NMDA receptor subunit expression. These results extend prior research into the role of DCS in neural-immune interactions, and indicate that the detrimental effects of peripheral LPS administration on consolidation of contextual fear memory may be ameliorated with DCS treatment, though the mechanisms underlying these effects are currently unclear.
Behavioural brain research 01/2013; 243(1). DOI:10.1016/j.bbr.2012.12.053 · 3.03 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.